The potential for CETP inhibition to reduce cardiovascular disease risk.
BACKGROUND: Although reductions in cardiovascular risk can be achieved by lowering low-density lipoprotein cholesterol, treated patients remain at substantial risk. Epidemiological studies have established that higher levels of high-density lipoprotein cholesterol (HDL-C) are strongly associated wi...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2006
|
| _version_ | 1826261950122688512 |
|---|---|
| author | Ansell, B Hobbs, F |
| author_facet | Ansell, B Hobbs, F |
| author_sort | Ansell, B |
| collection | OXFORD |
| description | BACKGROUND: Although reductions in cardiovascular risk can be achieved by lowering low-density lipoprotein cholesterol, treated patients remain at substantial risk. Epidemiological studies have established that higher levels of high-density lipoprotein cholesterol (HDL-C) are strongly associated with reduced cardiovascular risk, and therefore raising levels of HDL-C may be beneficial. The activity of cholesteryl ester transfer protein (CETP) appears to be inversely correlated with HDL-C levels and thus CETP is an attractive target for intervention to raise levels of HDL-C and potentially reduce residual cardiovascular risk. OBJECTIVES: This paper reviews the evidence for an atheroprotective role of higher levels of HDL-C, the function of CETP in cholesterol metabolism, and the concept of CETP inhibition as a potential new strategy for decreasing cardiovascular risk. An analysis of clinical studies of CETP inhibition was also performed. METHODS: MEDLINE (1966 to June 2006), EMBASE (1974 to June 2006), and cardiology conference proceedings were searched for clinical trials of CETP inhibition. RESULTS: Thirteen reports involving vaccine-based and pharmacological inhibition of CETP were found. Modest and inconsistent elevation of HDL-C was observed with vaccine-based therapy, whereas HDL-C elevation with pharmacological inhibitors was greater and more consistent. CONCLUSIONS: Elevation of HDL-C via CETP inhibition appears to be a potentially promising approach to reduce cardiovascular disease. Preliminary studies suggest benefits of CETP inhibition on serum lipid levels, and ongoing studies should establish the effects on atherosclerosis and cardiovascular events. |
| first_indexed | 2024-03-06T19:28:38Z |
| format | Journal article |
| id | oxford-uuid:1cadaea7-0a29-4a7e-be28-ab5a51f2e3bc |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:28:38Z |
| publishDate | 2006 |
| record_format | dspace |
| spelling | oxford-uuid:1cadaea7-0a29-4a7e-be28-ab5a51f2e3bc2022-03-26T11:06:48ZThe potential for CETP inhibition to reduce cardiovascular disease risk.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:1cadaea7-0a29-4a7e-be28-ab5a51f2e3bcEnglishSymplectic Elements at Oxford2006Ansell, BHobbs, F BACKGROUND: Although reductions in cardiovascular risk can be achieved by lowering low-density lipoprotein cholesterol, treated patients remain at substantial risk. Epidemiological studies have established that higher levels of high-density lipoprotein cholesterol (HDL-C) are strongly associated with reduced cardiovascular risk, and therefore raising levels of HDL-C may be beneficial. The activity of cholesteryl ester transfer protein (CETP) appears to be inversely correlated with HDL-C levels and thus CETP is an attractive target for intervention to raise levels of HDL-C and potentially reduce residual cardiovascular risk. OBJECTIVES: This paper reviews the evidence for an atheroprotective role of higher levels of HDL-C, the function of CETP in cholesterol metabolism, and the concept of CETP inhibition as a potential new strategy for decreasing cardiovascular risk. An analysis of clinical studies of CETP inhibition was also performed. METHODS: MEDLINE (1966 to June 2006), EMBASE (1974 to June 2006), and cardiology conference proceedings were searched for clinical trials of CETP inhibition. RESULTS: Thirteen reports involving vaccine-based and pharmacological inhibition of CETP were found. Modest and inconsistent elevation of HDL-C was observed with vaccine-based therapy, whereas HDL-C elevation with pharmacological inhibitors was greater and more consistent. CONCLUSIONS: Elevation of HDL-C via CETP inhibition appears to be a potentially promising approach to reduce cardiovascular disease. Preliminary studies suggest benefits of CETP inhibition on serum lipid levels, and ongoing studies should establish the effects on atherosclerosis and cardiovascular events. |
| spellingShingle | Ansell, B Hobbs, F The potential for CETP inhibition to reduce cardiovascular disease risk. |
| title | The potential for CETP inhibition to reduce cardiovascular disease risk. |
| title_full | The potential for CETP inhibition to reduce cardiovascular disease risk. |
| title_fullStr | The potential for CETP inhibition to reduce cardiovascular disease risk. |
| title_full_unstemmed | The potential for CETP inhibition to reduce cardiovascular disease risk. |
| title_short | The potential for CETP inhibition to reduce cardiovascular disease risk. |
| title_sort | potential for cetp inhibition to reduce cardiovascular disease risk |
| work_keys_str_mv | AT ansellb thepotentialforcetpinhibitiontoreducecardiovasculardiseaserisk AT hobbsf thepotentialforcetpinhibitiontoreducecardiovasculardiseaserisk AT ansellb potentialforcetpinhibitiontoreducecardiovasculardiseaserisk AT hobbsf potentialforcetpinhibitiontoreducecardiovasculardiseaserisk |